For: | Zhong JH. Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era. World J Gastroenterol 2024; 30(8): 806-810 [PMID: 38516235 DOI: 10.3748/wjg.v30.i8.806] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v30/i8/806.htm |
Number | Citing Articles |
1 |
Jia‐Yong Su, Kang Chen, Zhen Liu, Min Luo, Shao‐Ping Liu, Jun‐Jie Ou, Ze Su, Wen‐Feng Li, Wen‐Hai He, Ning Peng, Liang Ma, Bang‐De Xiang, Jian‐Hong Zhong. Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies. Alimentary Pharmacology & Therapeutics 2025; doi: 10.1111/apt.70102
|
2 |
Jin-Ming Wang, Guo-Gao Qiu, Zhi-Dong Liu, Jia-Yong Su, Da-Long Yang, Zhu-Jian Deng, Zhi-Cheng Li, Jian-Hong Zhong. Treatment for unresectable hepatocellular carcinoma patients: Options and management after complete response. iLIVER 2025; 4(1): 100145 doi: 10.1016/j.iliver.2025.100145
|
3 |
Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang, Ming-Hui Li. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World Journal of Hepatology 2024; 16(10): 1158-1168 doi: 10.4254/wjh.v16.i10.1158
|
4 |
Wei-Hua Cao, Ya-Qin Zhang, Xin-Xin Li, Zi-Yu Zhang, Ming-Hui Li. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World Journal of Hepatology 2024; 16(10): 1338 doi: 10.4254/wjh.v16.i10.1338
|
5 |
Lakshmi Rajdev, Gentry G. King, Christopher H. Lieu, Stacey A. Cohen, Shubham Pant, Nataliya V. Uboha, Dustin Deming, Midhun Malla, Anup Kasi, Kelsey Klute, Kristen R. Spencer, Arvind Dasari, Van K. Morris, Gregory Botta, Andrew M. Lowy, Mark H. O'Hara, Jennifer Eads, Daniel King, Manish A. Shah, Theodore S. Hong, Aparna Parikh, Samuel J. Klempner, Salma K. Jabbour, Akhil Chawla, Daniela Molena, Thomas J. George, Michael K. Gibson, Carmen Allegra, Karyn Goodman, Cathy Eng, Philip A. Philip. Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group. JCO Precision Oncology 2025; (9) doi: 10.1200/PO-24-00489
|